325 related articles for article (PubMed ID: 16553505)
1. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study.
Etminan M; Zhang B; Fitzgerald M; Brophy JM
Pharmacotherapy; 2006 Apr; 26(4):479-82. PubMed ID: 16553505
[TBL] [Abstract][Full Text] [Related]
2. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
Mancini GB; Etminan M; Zhang B; Levesque LE; FitzGerald JM; Brophy JM
J Am Coll Cardiol; 2006 Jun; 47(12):2554-60. PubMed ID: 16781387
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients.
Liu CL; Shau WY; Wu CS; Lai MS
J Hypertens; 2012 Nov; 30(11):2223-9. PubMed ID: 22929610
[TBL] [Abstract][Full Text] [Related]
6. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study.
Antoniou T; Gomes T; Juurlink DN; Loutfy MR; Glazier RH; Mamdani MM
Arch Intern Med; 2010 Jun; 170(12):1045-9. PubMed ID: 20585070
[TBL] [Abstract][Full Text] [Related]
7. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene.
Takahashi T; Morimoto S; Okaishi K; Kanda T; Nakahashi T; Okuro M; Murai H; Nishimura Y; Iwai K; Matsumoto M
Am J Hypertens; 2005 Oct; 18(10):1353-9. PubMed ID: 16202861
[TBL] [Abstract][Full Text] [Related]
8. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population.
van de Garde EM; Souverein PC; van den Bosch JM; Deneer VH; Leufkens HG
Eur Respir J; 2006 Jun; 27(6):1217-22. PubMed ID: 16455828
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive medications and risk of community-acquired pneumonia.
Mukamal KJ; Ghimire S; Pandey R; O'Meara ES; Gautam S
J Hypertens; 2010 Feb; 28(2):401-5. PubMed ID: 20051911
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
Epstein BJ; Gums JG
Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
[TBL] [Abstract][Full Text] [Related]
13. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor blockers do not promote coronary collateral circulation in patients with coronary artery disease.
Imaizumi S; Miura S; Nishikawa H; Iwata A; Zhang B; Kawamura A; Tsuchiya Y; Kumagai K; Matsuo K; Saku K
Hypertens Res; 2006 Mar; 29(3):135-41. PubMed ID: 16755148
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
de Jong HJ; Vandebriel RJ; Saldi SR; van Dijk L; van Loveren H; Cohen Tervaert JW; Klungel OH
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):835-43. PubMed ID: 22674737
[TBL] [Abstract][Full Text] [Related]
18. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
20. Statin use and risk of epilepsy: a nested case-control study.
Etminan M; Samii A; Brophy JM
Neurology; 2010 Oct; 75(17):1496-500. PubMed ID: 20975051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
